Hvivo PLC (LON:HVO) insider James Winschel bought 30,602 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was acquired at an average cost of GBX 1,193 ($15.69) per share, for a total transaction of £365,081.86 ($480,244.49).

LON:HVO opened at GBX 13.88 ($0.18) on Friday. The firm’s fifty day simple moving average is GBX 12.49 and its 200 day simple moving average is GBX 16.72. The company has a current ratio of 1.37, a quick ratio of 1.16 and a debt-to-equity ratio of 25.11. Hvivo PLC has a twelve month low of GBX 9.75 ($0.13) and a twelve month high of GBX 41.40 ($0.54). The firm has a market capitalization of $11.58 million and a price-to-earnings ratio of -0.69.

Hvivo Company Profile

hVIVO plc, a specialty biopharma company, provides medical and scientific research services in the United Kingdom, the United States, and Europe. The company is developing a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases, including influenza virus, respiratory syncytial virus, asthma exacerbation, and human rhinovirus.

Read More: The limitations of an equal weight rating

Receive News & Ratings for Hvivo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo and related companies with MarketBeat.com's FREE daily email newsletter.